220 related articles for article (PubMed ID: 34164339)
21. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
Front Oncol; 2021; 11():654350. PubMed ID: 33954112
[TBL] [Abstract][Full Text] [Related]
22. A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma.
Xiao Y; Cui G; Ren X; Hao J; Zhang Y; Yang X; Wang Z; Zhu X; Wang H; Hao C; Duan H
Front Oncol; 2020; 10():605737. PubMed ID: 33381460
[TBL] [Abstract][Full Text] [Related]
23. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
24. Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.
Yang J; Shen L; Yang J; Qu Y; Gong C; Zhou F; Liu Y; Luo M; Zhao L
Transl Cancer Res; 2024 Jan; 13(1):112-136. PubMed ID: 38410234
[TBL] [Abstract][Full Text] [Related]
25. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
26. Screening TCGA database for prognostic genes in lower grade glioma microenvironment.
Ni J; Liu S; Qi F; Li X; Yu S; Feng J; Zheng Y
Ann Transl Med; 2020 Mar; 8(5):209. PubMed ID: 32309356
[TBL] [Abstract][Full Text] [Related]
27. Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.
Ye L; Xu Y; Hu P; Wang L; Yang J; Yuan F; Wang Y; Zhang C; Tian D; Chen Q
Front Mol Neurosci; 2021; 14():720899. PubMed ID: 34776862
[No Abstract] [Full Text] [Related]
28. A prognostic signature of five pseudogenes for predicting lower-grade gliomas.
Liu B; Liu J; Liu K; Huang H; Li Y; Hu X; Wang K; Cao H; Cheng Q
Biomed Pharmacother; 2019 Sep; 117():109116. PubMed ID: 31247469
[TBL] [Abstract][Full Text] [Related]
29. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.
Bai Z; Wang X; Zhang Z
Front Genet; 2022; 13():655169. PubMed ID: 35281815
[No Abstract] [Full Text] [Related]
30. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
31. A Novel Six Autophagy-Related Genes Signature Associated With Outcomes and Immune Microenvironment in Lower-Grade Glioma.
Lin T; Cheng H; Liu D; Wen L; Kang J; Xu L; Shan C; Chen Z; Li H; Lai M; Zhou Z; Hong W; Hu Q; Li S; Zhou C; Geng J; Jin X
Front Genet; 2021; 12():698284. PubMed ID: 34721517
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Guo F; Hong J
Front Genet; 2020; 11():441. PubMed ID: 32431729
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma.
Feng S; Liu H; Dong X; Du P; Guo H; Pang Q
Bioengineered; 2021 Dec; 12(2):9692-9708. PubMed ID: 34696669
[TBL] [Abstract][Full Text] [Related]
34. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature.
Zheng J; Wu Z; Qiu Y; Wang X; Jiang X
J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and Predictive Value of Immune-Related Gene Pair Signature in Primary Lower-Grade Glioma Patients.
Lei K; Li J; Tu Z; Liu F; Ye M; Wu M; Zhu Y; Luo M; Lin L; Tao C; Huang K; Zhu X
Front Oncol; 2021; 11():665870. PubMed ID: 34123829
[TBL] [Abstract][Full Text] [Related]
36. CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment.
Wang F; Tao Z; Tian Z; Jin J; Dong J; Dai Y; Yu W; Tang B; Hu S
Front Genet; 2022; 13():874896. PubMed ID: 35865011
[No Abstract] [Full Text] [Related]
37. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
38. Integrated analysis of necroptosis related gene signature to predict clinical outcomes, immune status and drug sensitivity in lower grade Glioma.
Hu X; Ma Y; Xia Y; Liu B
Heliyon; 2024 Jan; 10(1):e23947. PubMed ID: 38192784
[TBL] [Abstract][Full Text] [Related]
39. New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis.
Chen D; Yao J; Hu B; Kuang L; Xu B; Liu H; Dou C; Wang G; Guo M
Chin Neurosurg J; 2022 May; 8(1):12. PubMed ID: 35585639
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive investigation of the prognostic values and molecular mechanisms of syntaxin binding protein 5 antisense RNA 1 in patients with colon adenocarcinoma based on RNA sequencing dataset.
Wei H; Tang L; Wang J; Ni M; Liao X; Guo E
J Cancer; 2023; 14(9):1607-1622. PubMed ID: 37325053
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]